2024

1. A robust clustering strategy for stratification unveils unique patient subgroups in acutely decompensated cirrhosis

   Journal of Translational Medicine, Vol. 22, Núm. 1

2. An artificial intelligence-assisted system versus white light endoscopy alone for adenoma detection in individuals with Lynch syndrome (TIMELY): an international, multicentre, randomised controlled trial

   The Lancet Gastroenterology and Hepatology, Vol. 9, Núm. 9, pp. 802-810

3. Belantamab mafodotin: an important treatment option for vulnerable patients with triple class exposed relapsed and/or refractory multiple myeloma

   Haematologica

4. Clinical practice in European centres treating paediatric posterior fossa tumours with pencil beam scanning proton therapy

   Radiotherapy and Oncology, Vol. 198

5. Daratumumab, Bortezomib, Lenalidomide, and Dexamethasone for Multiple Myeloma.

   New England Journal of Medicine, Vol. 390, Núm. 4, pp. 301-313

6. Factors Impacting Survival After Transarterial Radioembolization in Patients with Unresectable Intrahepatic Cholangiocarcinoma: A Combined Analysis of the Prospective CIRT Studies

   CardioVascular and Interventional Radiology, Vol. 47, Núm. 3, pp. 310-324

7. Gliomatosis cerebri in children: A poor prognostic phenotype of diffuse gliomas with a distinct molecular profile

   Neuro-oncology, Vol. 26, Núm. 9, pp. 1723-1737

8. Health-related quality of life in patients with newly diagnosed advanced ovarian cancer treated with niraparib vs placebo: Results from the phase 3 randomized PRIMA/ENGOT-OV26/GOG-3012 trial

   Gynecologic Oncology, Vol. 184, pp. 168-177

9. Health-related quality of life in patients with triple-class exposed relapsed and refractory multiple myeloma treated with idecabtagene vicleucel or standard regimens: patient-reported outcomes from the phase 3, randomised, open-label KarMMa-3 clinical trial

   The Lancet Haematology, Vol. 11, Núm. 3, pp. e216-e227

10. Mixed responses to targeted therapy driven by chromosomal instability through p53 dysfunction and genome doubling

    Nature Communications, Vol. 15, Núm. 1

11. Multidisciplinary Delphi Consensus on Safety of Combining Transarterial Radioembolization with Yttrium-90 Microspheres with Systemic Anticancer Agents for the Treatment of Liver Malignancy

    Journal of Vascular and Interventional Radiology, Vol. 35, Núm. 9, pp. 1253-1267.e1

12. Phase 1, first-in-human study of TYRP1-TCB (RO7293583), a novel TYRP1-targeting CD3 T-cell engager, in metastatic melanoma: active drug monitoring to assess the impact of immune response on drug exposure

    Frontiers in Oncology, Vol. 14

13. Plain language summary of the KarMMa-3 study of ide-cel or standard of care regimens in people with relapsed or refractory multiple myeloma

    Future Oncology, Vol. 20, Núm. 18, pp. 1221-1235

14. Predictors of long-term progression-free survival in patients with ovarian cancer treated with niraparib in the PRIMA/ENGOT-OV26/GOG-3012 study

    International journal of gynecological cancer : official journal of the International Gynecological Cancer Society, Vol. 34, Núm. 7, pp. 1041-1050

15. Recent outcomes of liver transplantation for Budd-Chiari syndrome: A study of the European Liver Transplant Registry (ELTR) and affiliated centers

    Hepatology, Vol. 80, Núm. 1, pp. 136-151

16. Report on palliative sedation medication usage: a survey of palliative care experts in Eight European countries

    BMC Palliative Care, Vol. 23, Núm. 1

17. Representation of genomic intratumor heterogeneity in multi-region non-small cell lung cancer patient-derived xenograft models

    Nature Communications , Vol. 15, Núm. 1

18. Revised European Association for Palliative Care (EAPC) recommended framework on palliative sedation: An international Delphi study

    Palliative Medicine, Vol. 38, Núm. 2, pp. 213-228

19. SENECA study: staging endometrial cancer based on molecular classification

    International journal of gynecological cancer : official journal of the International Gynecological Cancer Society, Vol. 34, Núm. 9, pp. 1313-1321

20. Skeletal muscle quality predicts overall survival in advanced liver hepatocellular carcinoma treated with SIRT and sorafenib: A subanalysis of the SORAMIC trial

    United European Gastroenterology Journal